Efficacy and safety of S-1 in patients with metastatic breast cancer: Retrospective review in a single institution

Oncology

Volumn 79, Issue 3-4, 2011, Pages 273-277

  Hara, Fumikata ^a   Kiyoto, Sachiko ^a   Takahashi, Mina ^a   Takabatake, Daisuke ^a   Takashima, Seiki ^a   Aogi, Kenjiro ^a   Ohsumi, Shozo ^a   Takashima, Shigemitsu ^a  

^a NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Metastatic breast cancer; Quality of life; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE DERIVATIVE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; IXABEPILONE; NAVELBINE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ANOREXIA; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; FATIGUE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MEDICAL RECORD REVIEW; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT CANCER; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SOFT TISSUE METASTASIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BONE NEOPLASMS; BREAST NEOPLASMS; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; OXONIC ACID; RETROSPECTIVE STUDIES; SURVIVAL RATE; TEGAFUR; TREATMENT OUTCOME;

EID: 79952104921     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322371     Document Type: Review

References (18)

1. Japanese Breast Cancer Society EBM Guideline for drug therapy. 2007, pp 91-95.
2. Hortobagyi GN: Treatment of breast cancer. N Engl J Med 1998; 339:974-984. (Pubitemid 28455101)
3. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remis-sion following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197-2205. (Pubitemid 26264869)
4. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oya-ma K, Takeda S, Unemi N, Fukushima M: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potas-sium oxonate (S-1) against human colon car-cinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 2602-2606. (Pubitemid 26171684)
5. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxic-ity of 5-fluorouracil by two biochemical mod-ulators. Anticancer Drugs 1996; 7:548-557. (Pubitemid 26276346)
6. Takechi T, Nakano K, Uchida J, Mita A, Toko K, Takeda S, Unemi N, Shirasaka T: Antitu-mor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in ex-perimental tumor models in rats. Cancer Chemother Pharmacol 1997; 39:205-211. (Pubitemid 26414256)
7. Saeki T, Takashima S, Sano M, Horikoshi N Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, Noguchi S, Taguchi T: A phase II study of S-1 in patients with meta-static breast cancer: a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 2004; 11: 194-202.
8. Hino M, Saeki T, Sato Y, Sano M, S-1 Coop-erative Study Group, Breast Cancer Working Group: Late phase II study of S-1 in patients with taxane resistant breast cancer. ASCO Ann Meet Abstr 745. J Clin Oncol 2004; 22(14S):745.
9. Shien T, Shimizu C, Akashi-Tanaka S, Yo-nemori K, Kohno T, Hojo T, Ando M, Katsu-mata N, Kinoshita T, Fujiwara Y: Clinical ef-ficacy of S-1 in pretreated metastatic breast cancer patients. Jpn J Clin Oncol 2008; 38: 172-175. (Pubitemid 351419739)
10. Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I: Oral capecitabine in anthracycline-and taxane-pretreated ad-vanced/metastatic breast cancer. Acta Oncol 2004; 43: 186-189. (Pubitemid 38478906)
11. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multi-center, phase II study of capecitabine in tax-ane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759-1768. (Pubitemid 32952493)
12. Fumoleau P, Largillier R, Clippe C, Dièras V, Orfeuvre H Lesimple T, Culine S, Audhuy B, Serin D, Curé H, Vuillemin E, Morère JF, Montestruc F, Mouri Z, Namer M: Multicen-tre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast Cancer. Eur J Cancer 2004; 40: 536-542. (Pubitemid 38220770)
13. Reichardt P, Von Minckwitz G, Thuss-Pa-tience PC, Jonat W, Kölbl H, Jänicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Lück HJ: Mul-ticenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a tax-ane-containing therapy. Ann Oncol 2003; 14:1227-1233. (Pubitemid 37039048)
14. Pierga JY, Fumoleau P, Brewer Y, Zelek L, Martin D, Turpin FL, Goudier MJ, Gil-Del-gado M, Baticle JL, Namer M, Chollet P, Sutherland W, Barats JC; Cooperative Group of the French Capecitabine Compassionate Use Program: Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French Com-passionate Use Program. Breast Cancer Res Treat 2004; 88:117-129. (Pubitemid 39585185)
15. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ: A randomised multicentre phase II trial of capecitabine vs. S-1 as first-line treat-ment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 2008; 99: 584-590.
16. Ito Y, Osaki Y, Tokudome N, Sugihara T, Takahashi S, Iwase T, Hatake K: Efficacy of S-1 in heavily pretreated patients with meta-static breast cancer: cross-resistance to capecitabine. Breast Cancer 2009; 16:126-131.
17. Vallböhmer D, Yang DY, Kuramochi H, Shimizu D, Danenberg KD, Lindebjerg J, Nielsen JN, Jakobsen A, Danenberg PV: DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int J Oncol 2007; 31:413-418.
18. Fujiwara H, Terashima M, Irinoda T, Taka-gane A, Abe K, Nakaya T, Yonezawa H, Oya-ma K, Takahashi M, Saito K, Takechi T, Fu-kushima M, Shirasaka T: Superior antitu-mour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 2003; 39:2387-2394. (Pubitemid 37214864)